The ARNT Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the HAP1 line, with targeted disruption of the ARNT gene. This heterogeneous pool provides a loss-of-function model for studying ARNT-dependent pathways without clonal selection biases. The polyclonal format averages off-target effects and is suitable for robust phenotypic screens.
HAP1 cells are a near-haploid human fibroblast-like cell line originating from a male chronic myeloid leukemia (CML) patient. Their haploid karyotype simplifies knockout studies, as a single gene disruption can yield a complete loss-of-function allele. HAP1 cells are widely employed in genetic screening and functional genomics due to their stable growth and retention of key signaling pathways.
ARNT is a constitutively expressed bHLH-PAS transcription factor that functions as an obligate heterodimerization partner for signal-activated proteins such as AhR and HIF-1??. Upon activation by xenobiotic ligands (e.g., TCDD) or hypoxia, AhR or HIF-1?? dimerize with ARNT, translocate to the nucleus, and bind to XRE or HRE elements in target gene promoters. This complex drives expression of genes including CYP1A1, CYP1B1, VEGF, EPO, GLUT1, and PDK1, thereby regulating xenobiotic metabolism, angiogenesis, and metabolic adaptation. ARNT also interacts with BMAL1, CLOCK, and HIF-2??, contributing to circadian rhythm and hypoxic responses. Upstream signals from PI3K/AKT/mTOR and ERK pathways further modulate ARNT-containing complexes.
In the HAP1 background, ARNT disruption cleanly ablates its function due to the haploid genome, enabling unambiguous analysis of AhR and HIF-1?? pathways. For instance, loss of ARNT prevents TCDD-induced CYP1A1 expression and blunts hypoxia-driven VEGF upregulation. This model is valuable for analyzing ARNT??s role in leukemia-related signaling and for screening chemicals that require AhR-mediated metabolic activation.
Typical applications include western blotting for ARNT, RT-qPCR for CYP1A1 and VEGF, luciferase reporter assays for AhR activity, migration assays under hypoxia, and ChIP-qPCR for target promoter occupancy. The cells support toxicology screens, drug metabolism studies, and cancer biology research. For further information, please contact Ascent Research.
